神経筋遮断薬の世界市場レポート 2025年

神経筋遮断薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.1％で49億8,000万米ドルに成長します。予測期間の成長は、規制当局の承認、外来および日帰り手術の増加、医療ツーリズムと戦略的提携の拡大、筋骨格系障害の有病率の増加、外科手術の有病率の増加に起因しています。予測期間における主な動向としては、非鎮静性製剤の開発、新規NMBDの開発、個別化医療の進展、併用療法の開発、患者中心の医薬品開発などが挙げられます。

外科手術の増加は、今後の神経筋遮断薬市場の拡大を牽引すると予想されます。外科的処置とは、傷害、疾患、状態を治療するための切開、切除、その他の手技を伴う医療介入です。このような外科手術の増加は、診断ツールの進歩、ヘルスケアへのアクセスの向上、QOL重視の高まり、患者の意識と期待の高まりに起因しています。神経筋遮断薬は、筋弛緩を誘発し、様々な外科的側面を補助するために、これらの処置に利用されています。例えば2023年9月、米国を拠点とする専門組織である米国形成外科学会の報告書によると、2022年には米国で合計2,620万件の外科的・低侵襲的な美容整形・再建手術が行われたことが明らかになりました。その結果、外科手術の頻度の増加が神経筋遮断薬市場の成長に拍車をかけています。

神経筋遮断薬市場の主要企業は、戦略的提携を通じて製品ラインを拡大し、市場へのリーチを強化するとともに、ドラッグの製剤やデリバリー方法のイノベーションを推進しています。このような提携には、製品開発を進めるためのリソースや専門知識を共有するパートナーシップが含まれます。例えば、2022年5月、インドの製薬会社BDRファーマは、同じくインドの製薬メーカーであるバレンヤム・ヘルスケアと提携し、スグマデックスを発売しました。スグマデックスは、浅いNMB、中程度のNMB、深いNMBを含む神経筋ブロック（NMB）を安全、迅速、完全に反転させ、麻酔効果を効果的に除去する新規麻酔薬です。深部NMBに対応し、術後の呼吸器合併症を軽減します。2mlと5mlの単回投与バイアルがあり、効率と患者の安全性を高めます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界神経筋遮断薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の神経筋遮断薬市場：成長率分析
• 世界の神経筋遮断薬市場の実績：規模と成長, 2019-2024
• 世界の神経筋遮断薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界神経筋遮断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の神経筋遮断薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非分極剤
• 脱分極剤
• 世界の神経筋遮断薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の用途
• 世界の神経筋遮断薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の神経筋遮断薬市場非分極剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベンジルイソキノリン
• ステロイド剤
• 長時間作用型薬剤
• 中間作用剤
• 短時間作用型薬剤
• 世界の神経筋遮断薬市場脱分極剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サクシニルコリン
• サクシニルコリンの類似体
• 速効性薬剤
• 短時間作用型薬剤
• 中間作用剤

第7章 地域別・国別分析

• 世界の神経筋遮断薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経筋遮断薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経筋遮断薬市場：競合情勢
• 神経筋遮断薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Limited
• Baxter International Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• UCB Pharma S.A.
• Eisai Co Ltd.
• Ipsen S.A.
• B. Braun Melsungen AG
• Aurobindo Pharma Limited
• Hikma Pharmaceuticals PLC
• Mallinckrodt Pharmaceuticals plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経筋遮断薬市場2029：新たな機会を提供する国
• 神経筋遮断薬市場2029：新たな機会を提供するセグメント
• 神経筋遮断薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A neuromuscular blocking drug is a medication that disrupts the transmission of nerve impulses to muscles, resulting in the temporary paralysis of skeletal muscles. These drugs function by either blocking the action of acetylcholine, a neurotransmitter, at the neuromuscular junction-where nerves and muscles communicate-or by mimicking acetylcholine and overstimulating the muscle receptor, causing it to become unresponsive. Neuromuscular blocking drugs are mainly used in medical settings, particularly during surgeries or other procedures, to facilitate intubation (the insertion of a breathing tube) and ensure muscle relaxation.

The primary types of neuromuscular blocking drugs are non-depolarizing agents and depolarizing agents. Non-depolarizing agents act by competing with acetylcholine at the neuromuscular junction, preventing muscle contraction. These drugs are available through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and serve a range of end users, such as hospitals, homecare, specialty clinics, and others.

The neuromuscular blocking drugs market research report is one of a series of new reports from The Business Research Company that provides neuromuscular blocking drugs market statistics, including neuromuscular blocking drugs industry global market size, regional shares, competitors with a neuromuscular blocking drugs market share, detailed neuromuscular blocking drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neuromuscular blocking drugs industry. This neuromuscular blocking drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuromuscular blocking drug market size has grown strongly in recent years. It will grow from $3.87 $ billion in 2024 to $4.08 $ billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased prevalence of conditions, increased awareness and training, increased healthcare spending, improved drug reversibility, and rise emphasis on patient safety.

The neuromuscular blocking drug market size is expected to see strong growth in the next few years. It will grow to $4.98 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to regulatory approvals, growth in outpatient and day surgeries, the expansion of medical tourism and strategic alliances, the growing prevalence of musculoskeletal disorders, and the increasing prevalence of surgical procedures. Major trends in the forecast period include the development of non-sedative formulations, the development of new NMBDs, advances in personalized medicine, the development of combination therapies, and patient-centric drug development.

The growing number of surgical procedures is expected to drive the expansion of the neuromuscular blocking drug market in the future. Surgical procedures are medical interventions that involve incisions, excisions, or other techniques to treat injuries, diseases, or conditions. This rise in surgical procedures is attributed to advancements in diagnostic tools, better access to healthcare, an increased focus on quality of life, and growing patient awareness and expectations. Neuromuscular blocking drugs are utilized in these procedures to induce muscle relaxation and aid in various surgical aspects. For example, in September 2023, a report by the American Society of Plastic Surgeons, a professional organization based in the US, revealed that in 2022, a total of 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were performed in the United States. As a result, the increasing frequency of surgical procedures is fueling the growth of the neuromuscular blocking drug market.

Major companies in the neuromuscular blocking drug market are expanding their product lines through strategic collaborations to enhance market reach and drive innovation in drug formulations and delivery methods. These collaborations involve partnerships that leverage shared resources and expertise to advance product development. For instance, in May 2022, BDR Pharma, an India-based pharmaceutical company, partnered with Varenyam Healthcare, another India-based pharmaceutical manufacturer, to launch Sugmadex. Sugmadex is a novel anesthesia drug that provides a safe, rapid, and complete reversal of neuromuscular block (NMB), including shallow, moderate, and deep NMB, thus effectively eliminating anesthesia effects. It addresses profound NMB and reduces post-operative respiratory complications, available in 2 ml and 5 ml single-dose vials, enhancing efficiency and patient safety.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals for an undisclosed amount. This acquisition aims to strengthen Biogen's rare disease portfolio by incorporating Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia, complementing its existing treatments for spinal muscular atrophy and amyotrophic lateral sclerosis. This move addresses unmet medical needs and drives growth in the market. Reata Pharmaceuticals is a US-based company specializing in rare neuromuscular blocking drugs.

Major companies operating in the neuromuscular blocking drug market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Bayer AG, Fresenius Kabi AG, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Baxter International Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, UCB Pharma S.A., Eisai Co Ltd., Ipsen S.A., B. Braun Melsungen AG, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals plc, Mylan N.V., Nippon Shinyaku Co Ltd., Sagent Pharmaceuticals Inc., Osmosis Inc., Cadila Healthcare Limited

North America was the largest region in the neuromuscular blocking drugmarket in 2023. The regions covered in the neuromuscular blocking drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuromuscular blocking drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuromuscular blocking drug market consists of sales of ganta curium, rapacuronium, alcuronium, tubocurarine, and metocurine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromuscular Blocking Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuromuscular blocking drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuromuscular blocking drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuromuscular blocking drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-Polarizing Agents; Depolarizing Agents
• 2) By Application: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Others Applications
• 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Non-Polarizing Agents: Benzylisoquinolines; Steroidal Agents; Long-Acting Agents; Intermediate-Acting Agents; Short-Acting Agents;
• 2) By Depolarizing Agents: Succinylcholine; Analogues of Succinylcholine; Rapid-Onset Agents; Short-Acting Agents; Intermediate-Acting Agents
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; AbbVie Inc.; Bayer AG; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuromuscular Blocking Drug Market Characteristics

3. Neuromuscular Blocking Drug Market Trends And Strategies

4. Neuromuscular Blocking Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neuromuscular Blocking Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neuromuscular Blocking Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neuromuscular Blocking Drug Market Growth Rate Analysis
• 5.4. Global Neuromuscular Blocking Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neuromuscular Blocking Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neuromuscular Blocking Drug Total Addressable Market (TAM)

6. Neuromuscular Blocking Drug Market Segmentation

• 6.1. Global Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Polarizing Agents
• Depolarizing Agents
• 6.2. Global Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Applications
• 6.3. Global Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.4. Global Neuromuscular Blocking Drug Market, Sub-Segmentation Of Non-Polarizing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benzylisoquinolines
• Steroidal Agents
• Long-Acting Agents
• Intermediate-Acting Agents
• Short-Acting Agents
• 6.5. Global Neuromuscular Blocking Drug Market, Sub-Segmentation Of Depolarizing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Succinylcholine
• Analogues of Succinylcholine
• Rapid-Onset Agents
• Short-Acting Agents
• Intermediate-Acting Agents

7. Neuromuscular Blocking Drug Market Regional And Country Analysis

• 7.1. Global Neuromuscular Blocking Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neuromuscular Blocking Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuromuscular Blocking Drug Market

• 8.1. Asia-Pacific Neuromuscular Blocking Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuromuscular Blocking Drug Market

• 9.1. China Neuromuscular Blocking Drug Market Overview
• 9.2. China Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuromuscular Blocking Drug Market

• 10.1. India Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuromuscular Blocking Drug Market

• 11.1. Japan Neuromuscular Blocking Drug Market Overview
• 11.2. Japan Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuromuscular Blocking Drug Market

• 12.1. Australia Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuromuscular Blocking Drug Market

• 13.1. Indonesia Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuromuscular Blocking Drug Market

• 14.1. South Korea Neuromuscular Blocking Drug Market Overview
• 14.2. South Korea Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuromuscular Blocking Drug Market

• 15.1. Western Europe Neuromuscular Blocking Drug Market Overview
• 15.2. Western Europe Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuromuscular Blocking Drug Market

• 16.1. UK Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuromuscular Blocking Drug Market

• 17.1. Germany Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuromuscular Blocking Drug Market

• 18.1. France Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuromuscular Blocking Drug Market

• 19.1. Italy Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuromuscular Blocking Drug Market

• 20.1. Spain Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuromuscular Blocking Drug Market

• 21.1. Eastern Europe Neuromuscular Blocking Drug Market Overview
• 21.2. Eastern Europe Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuromuscular Blocking Drug Market

• 22.1. Russia Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuromuscular Blocking Drug Market

• 23.1. North America Neuromuscular Blocking Drug Market Overview
• 23.2. North America Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuromuscular Blocking Drug Market

• 24.1. USA Neuromuscular Blocking Drug Market Overview
• 24.2. USA Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuromuscular Blocking Drug Market

• 25.1. Canada Neuromuscular Blocking Drug Market Overview
• 25.2. Canada Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuromuscular Blocking Drug Market

• 26.1. South America Neuromuscular Blocking Drug Market Overview
• 26.2. South America Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuromuscular Blocking Drug Market

• 27.1. Brazil Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuromuscular Blocking Drug Market

• 28.1. Middle East Neuromuscular Blocking Drug Market Overview
• 28.2. Middle East Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuromuscular Blocking Drug Market

• 29.1. Africa Neuromuscular Blocking Drug Market Overview
• 29.2. Africa Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuromuscular Blocking Drug Market Competitive Landscape And Company Profiles

• 30.1. Neuromuscular Blocking Drug Market Competitive Landscape
• 30.2. Neuromuscular Blocking Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Neuromuscular Blocking Drug Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Boehringer Ingelheim GmbH
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Baxter International Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. UCB Pharma S.A.
• 31.10. Eisai Co Ltd.
• 31.11. Ipsen S.A.
• 31.12. B. Braun Melsungen AG
• 31.13. Aurobindo Pharma Limited
• 31.14. Hikma Pharmaceuticals PLC
• 31.15. Mallinckrodt Pharmaceuticals plc

32. Global Neuromuscular Blocking Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromuscular Blocking Drug Market

34. Recent Developments In The Neuromuscular Blocking Drug Market

35. Neuromuscular Blocking Drug Market High Potential Countries, Segments and Strategies

• 35.1 Neuromuscular Blocking Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neuromuscular Blocking Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neuromuscular Blocking Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer